Table 1.
Clinical trials & FDA approved product of lymph node-targeted vaccine delivery systems.
| Catalog | Name | Company/Sponsor | Phase | Disease |
|---|---|---|---|---|
| Liposome | BNT162b2 | Pfizer&BioNTech | Approved 2020 | COVID-19 |
| CVnCoV | CureVac AG | Phase 3 | COVID-19 | |
| mRNA-1273 | ModernaTX, Inc. | Phase 3 | COVID-19 | |
| MPER-656 | NIAID | Phase 1 | HIV Infections | |
| BLP25 | ECOG-ACRIN Cancer Research Group | Phase 2 | Lung Cancer | |
| RNA-LP | University of Florida | Phase 1 | Adult Glioblastoma | |
| W_ova1 | BioNTech | Phase 1 | Ovarian Cancer | |
| GLA-LSQ | NIAID | Phase 1 | Plasmodium Falciparum Infections | |
| PDS0101 | M.D. Anderson Cancer Center | Phase 2 | Cervical Cancer | |
| Polymer | Grippol® Plus | NPO Petrovax | Phase 3 | Influenza Infections |
| DC cell | PROVENGE® | Dendreon | Approved 2010 | Prostatic Cancer |
| DC/AML vaccine | Dana-Farber Cancer Institute | Phase 2 | Acute Myelogenous Leukemia | |
| DC/MM fusion vaccine | NHLBI | Phase 2 | Multiple Myeloma | |
| Ad.p53-DC vaccines | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Small Cell Lung Cancer | |
| PEP-DC vaccine | Centre Hospitalier Universitaire Vaudois | Phase 1 | Pancreatic Adenocarcinoma | |
| HER-2 pulsed DC vaccine | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Breast Cancer | |
| MIDRIX4-LUNG DC vaccine | University Hospital, Ghent | Phase 1 | Non-small Cell Lung Cancer | |
| DC1 vaccine | Roswell Park Cancer Institute | Phase 2 | Cancer of Prostate | |
| MART-1 peptide DC vaccine | Jonsson Comprehensive Cancer Center | Phase 2 | Melanoma | |
| nDC vaccine | Radboud University | Phase 3 | Melanoma | |
| DC vaccine | Oslo University Hospital | Phase 3 | Glioblastoma | |
| Peptide/protein | EBV gp350-Ferritin vaccine | NIAID | Phase 1 | Epstein-Barr Virus Infections |
| Virus | ERVEBO® | Merck | Approved 2019 | Ebola Infections |
| Ad5-nCoV | CanSino Biologics Inc. | Approved 2021 | COVID-19 | |
| AZD1222 | AstraZeneca | Approved 2020 | COVID-19 | |
| Gam-COVID-Vac | Gamaleya Research Institute of Epidemiology and Microbiology | Approved 2020 | COVID-19 | |
| Ad26.COV2.S | Janssen Vaccines & Prevention B.V. | Approved 2020 | COVID-19 | |
| Ad26.ZEBOV | Janssen Vaccines & Prevention B.V. | Phase 3 | Ebola Infections | |
| Ad26.Mos4.HIV | Janssen Vaccines & Prevention B.V. | Phase 3 | HIV Infections | |
| ChAdOx1-HBV | Vaccitech Limited | Phase 1 | Hepatitis B Infections | |
| Ad26.RSV.preF | Janssen Vaccines & Prevention B.V. | Phase 2 | Respiratory syncytial virus Infections | |
| Ad5Ag85A | McMaster University | Phase 1 | Tuberculosis | |
| ChAdOx1-MVA 5 T4 | University of Oxford | Phase 2 | Prostate Cancer | |
| Ad-CEA | NCI | Phase 2 | Colorectal Tumors |